Time for an active antiviral therapy for hepatitis B: An update on the management of hepatitis B virus infection

Therapeutics and Clinical Risk Management

Volumn 3, Issue 4, 2007, Pages 605-612

  Chae, Hee Bok ^a,b,c   Hann, Hie Won ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Chungbuk National University Hospital   (South Korea)

Author keywords

Adefovir; Entecavir; Lamivudine; Pegylated interferon; Telbivudine; Tenofovir

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ALPHA2B INTERFERON; CLEVUDINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA2A; PRADEFOVIR; RECOMBINANT ALPHA2B INTERFERON; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TYZEKA; UNCLASSIFIED DRUG; VIRUS DNA;

ALOPECIA; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CANCER RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE COURSE; DRUG CLEARANCE; DRUG COST; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HEART FAILURE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY FAILURE; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LONG TERM CARE; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RADIOFREQUENCY ABLATION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SEROCONVERSION; SURVIVAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS CARRIER; VIRUS INHIBITION; VIRUS LOAD;

EID: 34848834146     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Barbon V, Marzano A, Carenzi M, et al. 2006. Treatment with adefovir alone or in combination with lamivudine in chronic hepatitis B lamivudine-resistant patients: results after two years. J Hepatol, 44:S178.
2. Bzowej N, Chan HLY, Lai CL, et al. 2006. A randomized trial of telbivudine (LdT) vs adefovir for HBeAg-positive chronic hepatitis B: final week 52 results. Hepatology, 44:563A.
3. Chae HB, Hann HW. 2006. Baseline HBV DNA level is the most important factor associated with viral breakthrough (BT) during lamivudine (LVD) therapy for chronic hepatitis B (CHB). Gastroenterology, 130:A846.
4. Chang T-T, Chao Y-C, Kaymakoglu S, et al. 2006a. Entecavir maintained virologic suppression through 3 years of treatment in antiviral naïve HBeAg(+) patients. Hepatology, 44:229A.
5. Chang T-T, Gish RG, de Man R, et al. 2006b. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med, 354:1001-10.
6. Chang TT, Gish RG, Hadziyannis SJ, et al. 2005. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology, 129:1198-209.
7. Chang TT, Lai CL, Chien RN, et al 2004. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Grastroenterol Hepatol, 19:1276-82.
8. Chen CJ, Yang HI, Su J, et al. 2006. REVEAL-HBV Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, 295:65-73.
9. Colonno RJ, Rose R, Pokornowski K et al. 2007. Four year assessment of entecavir resistance in nucleoside-naïve and lamivudine refractory patients. J Hepatol, 46 (Suppl 1): S294.
10. Conjeevaram HS, Lok AS. 2003. Management of chronic hepatitis B. J Hepatol, 38 (Suppl 1):S90-103.
11. Fung SK, Chae HB, Fontana RJ, et al. 2006. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol, 44:283-90.
12. Gane E, Safadi R, Xie Q, et al. 2006. A randomized trial of telbivudine (LdT) versus lamivudine in lamivudine experienced patients-week 24 primary analysis. Hepatology, 44(Suppl 1):564A.
13. Hadziyannis SJ, Tassopoulos NC, Chan TT, et al. 2005a. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with chronic hepatitis B: results after 5 years of therapy. J Hepatol, 42:754A.
14. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. 2005b. Adefovir Dipivoxil 438 study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med, 352:2673-81.
15. Hann HW, Chae HB, Dunn S. 2006. Tenofovir (TDF) has stronger antiviral effect than adefovir dipivoxil (ADV) against lamivudine (LVD) resistant hepatitis B virus (HBV). Gastroenterology, 130 (Suppl 2):A846.
16. Hann HWL, Funk MLJ, Rosenberg DM, et al. 2005. Factors associated with response to lamivudine: a retrosepctive study in a tertiary care clinic serving patients with chronic hepatitis B. J Gastroenterol and Hepatol, 20:433-40.
17. Keeffe EB, Dieterich DT, Han SH et al. 2006. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol, 4:936-62.
18. Lai CL, Gane B, Hsu CW, et al 2006. Two year results from the GLOBE trial in patients with chronic hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) Vs. Lamivudine. Hepatology, 44:222A.
19. Lai CL, Leung N, Teo EK, et al 2005. Telbivudine phase II investigator Group. 2005; A 1-year trial of telbivudine, lamivudine and the combination in patients with hepatitis Be Antigen-positive chronic hepatitis B. Gastroenterology, 129:528-36.
20. Lai CL, Shouval D, Lok AS, et al. 2006. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. New Engl J Med, 354:1011-20.
21. Lampertico P, Marzano A, Levrero M, et al. 2006. A multicenter Italian study of rescue adefovir dipivoxil therapy in lamivudine resistant patients: A 2 year analysis of 650 patients. J Hepatol, 44:S51.
22. Lau GK, Cooksley H, Ribiero RM, et al. 2004. Randomized double blind study comparing adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy versus ADV alone in HBeAg negative chronic hepatitis B: efficacy and mechanism of treatment response. Hepatology, 40:1155A.
23. Lau GK, Piratvisuth YT, Luo KX, et al. 2005. Peginterferon α-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med, 352:2682-95.
24. Lee HJ, Suh JI, Jang BI. 1997. The therapeutic effect of recombinant interferon α in chronic hepatitis B patients. Korean J of Gastroenterol, 29:777-85.
25. Lee WM. 1997. Medical progress: hepatitis B virus infection. N Engl J Med, 337:1733-45.
26. Lee YS, Suh DJ, Lim YS, et al. 2006. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology, 43:1385-91.
27. Leung N, Peng CY, Sollano J, et al. 2006. Entecavir results in higher HBV DNA reduction VS adefovir in chronically infected HBeAg(+) antiviral-naïve adults: 24 week results (E.A.R.L.Y. Study). Hepatology, 44(Suppl 1):554A.
28. Liaw YF, Leung N, Guan R, et al. 2003. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol hepatol, 18:239-45.
29. Liaw YF, Leung N, Guan R, et al. 2005. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver international, 25:472-89.
30. Liaw YF, Leung NW, Chang TT, et al. 2000. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asian Hepatitis Lamivudine Study Group. Gastroenterology, 119:172-80.
31. Liaw YF, Sung JJ, Chow WC, et al. 2004, Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 351:1521-31.
32. Lin CC, Wu JC, Chang TT, et al. 2001. Long-term evaluation of recombinant interferon alpha2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan. J Viral Hepatitis, 8:438-46.
33. Lok AS, Lai CL, Leung N, et al. 2003. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology, 125:1714-22.
34. Lok AS, Lai CL, Wu PC, et al. 1988. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet, 332:298-302.
35. Lok ASF, McMahon BJ. 2001. AASLD Practice guidelines: chronic hepatitis B. Hepatology, 34:1225-41.
36. Lok ASF, McMahon BJ. 2004. AASLD practice guidelines:chronic hepatitis B: update of recommendation. Hepatology, 39:857-61.
37. Marcellin P, Chang T, Lim S, et al. 2005. Increasing serologic, virologic and biochemical response over time to adefovir dipivoxil (ADV) 10 mg in HbeAg-positive chronic hepatitis B patients. J Hepatol, 42(Suppl 2):31.
38. Marcellin P, Chang T-T, Lim SG, et al. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med, 348:808-16.
39. Marcellin P, Lau GKK, Bonino F, et al. 2004. Peginterferon α-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 351:1206-17.
40. Martin P, Hann HW, Westerberg S, et al. 1998. Interferon-alpha2b therapy is efficacious in Asian-Americans with chronic hepatitis B infection: a prospective controlled trial. Dig Dis Sci, 43:875-9.
41. Nowak MA, Bonhoeffer S, Hill AM, et al. 1996. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci, 93:4398-402.
42. Nunez M, Perez-Olimeda M, Diaz B, et al. 2002, Activity of tenofovir on hepatitis B virus replicaion in HIV-co-infected patients failing or partially responding to lamivudine. AIDS, 16:2352-4.
43. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. 2005. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology, 42:121-9.
44. Perrillo RP. 2006. Therapy of hepatitis B-viral suppression or eradication? Hepatology, 43 (Suppl 1 ):S183-93.
45. Perrillo RP, Lai CL, Liaw YF, et al. 2002. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology, 36:186-94.
46. Perrillo RP, Schiff ER, Davis GL, et al. 1990. A randomized, controlled trial of interferon α-2b alone and after prednisolone withdrawal for the treatment of chronic hepatitis B. The hepatitis interventional therapy group. New Engl J Med, 323:295-301.
47. Prati D, Taiolo E, Zanella A, et al. 2002. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med, 137:1-10.
48. Ristig MB, Crippin J, Aberg JA, et al. 2002. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/ hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis, 186:1844-7.
49. Rosmawati M, Lai CL, Lao L, et al. 2003. Baseline ALT level does not predict viral load reduction in response to entecavir therapy. J of Hepatol 38:166, Abstr 574.
50. Ryu SH, Chung YH, Choi MH, et al. 2003. Long term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol, 39:614-19.
51. Snow A, Thibault V, Qi X, et al. 2005. Combination of adefovir (ADV) and lamivudine (LVD) prevented emergence of adefovir resistance mutations in chronic hepatitis B patients with lamivudine-resistant HBV. Gastroenterology, 128:A745.
52. Sung JJY, Lai YF, Zeuzem S, et al. 2003. A randomized, double-blind phase II study of lamivudine (LVD) compared o lamivudine plus adefovir dipivoxil (ADV) for treatment if naïve patients with chronic hepatitis B (CHB) week 52 analysis. J Hepatol, 38 (Suppl 2):25.
53. The EASL Jury. 2003. EASL international consensus conference on hepatitis B. J Hepatol, 38:533-40.
54. Van Bommel F, Wunsche T, Mauss S, et al. 2004. Comparison of adefovir and tenofovir in the treatment of lamivudine resistant hepatitis B virus infection. Hepatology, 40:1421-5.
55. Van Bommel F, Wensche T, Schurmann D, et al. 2003. A comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus (HBV) infection. Hepatology 38(Suppl 1):A246.
56. Yuen MF, Sabion E, Hui CK, et al. 2001. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology, 34:785-91.
57. Zeuzem S, de Man RA, Honkoop P et al. 1997. Dynamics of hepatitis B virus infection in vivo. J of Hepatol, 27:431-6.